DEA Rescheduling Proposal: What Moving Cannabis to Schedule III Actually Means
The DEA's proposed rule to move cannabis from Schedule I to Schedule III is the most significant federal cannabis policy shift in decades. Here is what it changes — and what it does not.
Sarah Chen
Founder & Editor-in-Chief, Cannabis Dispensary
The Drug Enforcement Administration's proposed rulemaking to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act represents the most consequential federal cannabis policy development since the Controlled Substances Act was enacted in 1970. But the details matter enormously — and much of the public commentary has conflated what rescheduling does with what it does not do.
What Schedule III Means
Under the Controlled Substances Act, Schedule I substances are defined as having no currently accepted medical use and a high potential for abuse. Schedule III substances, by contrast, are defined as having a currently accepted medical use and a moderate to low potential for physical dependence. Moving cannabis to Schedule III acknowledges what the medical and scientific community has recognized for decades: cannabis has accepted therapeutic applications and its abuse potential is substantially lower than Schedule I substances like heroin or Schedule II substances like fentanyl.
What Rescheduling Does
The most immediate practical effect of Schedule III rescheduling is the elimination of IRC Section 280E for cannabis businesses. Under current law, cannabis businesses cannot deduct ordinary business expenses because they are trafficking a Schedule I controlled substance. This has created effective tax rates of 60–80% for many cannabis operators. Schedule III rescheduling eliminates 280E, immediately improving the financial viability of licensed cannabis businesses nationwide.
Rescheduling also opens the door to federally funded cannabis research. Under Schedule I, researchers face extraordinary barriers to studying cannabis — limited supply, extensive DEA licensing requirements, and institutional resistance. Schedule III would substantially reduce these barriers and accelerate the clinical research pipeline.
What Rescheduling Does Not Do
Critically, Schedule III rescheduling does not legalize cannabis at the federal level. Possession, distribution, and cultivation of cannabis would remain federal crimes under the CSA. State-legal cannabis programs would continue to operate in a federal legal gray area. Interstate commerce in cannabis would remain prohibited. Banking access, while potentially improved at the margins, would not be fully resolved without separate legislation like the SAFER Banking Act.
Rescheduling also does not create a federal regulatory framework for cannabis products. The FDA would gain jurisdiction over cannabis as a Schedule III substance, but the agency has not indicated how it intends to exercise that jurisdiction — a significant source of uncertainty for the industry.
The Path Forward
The DEA rescheduling proposal is subject to a formal comment period and administrative law judge review before any final rule takes effect. Legal challenges from anti-cannabis advocacy groups are expected. The timeline to a final rule is measured in years, not months. But the direction of federal policy is now unambiguous: cannabis rescheduling is a matter of when, not if.